CD89 activation in therapy
US9522184B2 · kind B2 · utility
7Cited by
2References
31Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 14, 2011 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Apr 30, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.